Targeted Complement Activating Therapy — recombinant antibody platform designed to harness complement activation to kill pathogens; focus on multidrug-resistant organisms including Gram-negative and Gram-positive bacteria

Biotech Distilled coverage (8)

2026-07-06 UPDATE: Omeros (OMER) — Round Two on the Convert, and a Hint About Non-Dilutive Debt
2026-06-26 UPDATE: Omeros (OMER) — CHMP Says No, Re-Examination Coming
2026-06-18 UPDATE: Omeros (OMER) — Buying Back the Convert at 2x Face
2026-05-14 UPDATE: Omeros (OMER) - First Launch Quarter Prints $9.9M, NTAP Tailwind Stacks on the J-Code 🔒 Paid
2026-04-18 UPDATE: Omeros (OMER) – Permanent J-Code Clears the Runway 🔒 Paid
2026-04-05 UPDATE: Omeros (OMER) – Q4/YE 2025 Earnings, Launch Strategy, and Pipeline Nuance 🔒 Paid
2026-02-21 UPDATE: Omeros (OMER) - OncotoX Platform Shows Proof of Concept 🔒 Paid
2025-12-26 Omeros Corporation (OMER): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.